Bowman & Co S.C. Acquires 949 Shares of Johnson & Johnson (NYSE:JNJ)

Bowman & Co S.C. raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 9.4% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 11,012 shares of the company’s stock after acquiring an additional 949 shares during the period. Johnson & Johnson makes up 0.9% of Bowman & Co S.C.’s holdings, making the stock its 24th largest position. Bowman & Co S.C.’s holdings in Johnson & Johnson were worth $1,610,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Christopher J. Hasenberg Inc acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at about $31,000. WFA Asset Management Corp boosted its stake in Johnson & Johnson by 61.4% during the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock worth $40,000 after acquiring an additional 97 shares in the last quarter. MFA Wealth Advisors LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $43,000. Vermillion & White Wealth Management Group LLC bought a new stake in Johnson & Johnson in the fourth quarter worth $44,000. Finally, Disciplined Equity Management Inc. purchased a new position in Johnson & Johnson in the 4th quarter worth approximately $45,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on JNJ shares. Morgan Stanley raised their price objective on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a report on Thursday, July 18th. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 23rd. Royal Bank of Canada reissued an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research report on Tuesday, July 30th. TD Securities lowered their target price on shares of Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Monday, August 5th. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and a consensus target price of $173.21.

Johnson & Johnson Price Performance

JNJ traded up $1.75 during midday trading on Friday, hitting $164.10. The company had a trading volume of 7,089,147 shares, compared to its average volume of 7,299,449. The firm’s 50-day simple moving average is $153.92 and its 200-day simple moving average is $153.27. The company has a market capitalization of $394.94 billion, a PE ratio of 10.23, a P/E/G ratio of 2.63 and a beta of 0.52. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $167.78. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping the consensus estimate of $2.71 by $0.11. The firm had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business’s quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.80 earnings per share. Equities research analysts predict that Johnson & Johnson will post 10.07 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.02%. The ex-dividend date is Tuesday, August 27th. Johnson & Johnson’s payout ratio is currently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.